Ascendis Pharma A/S (NASDAQ:ASND) Receives $191.77 Average Price Target from Analysts

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) has earned a consensus rating of "Moderate Buy" from the thirteen brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $191.77.

A number of equities analysts have recently weighed in on ASND shares. Bank of America boosted their price target on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a "buy" rating in a report on Monday, September 23rd. Wells Fargo & Company boosted their target price on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an "overweight" rating in a research note on Tuesday, September 17th. Citigroup raised their price target on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a "buy" rating in a research note on Tuesday, September 17th. TD Cowen cut their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating for the company in a research report on Friday, November 15th. Finally, StockNews.com upgraded shares of Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Wednesday.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in Ascendis Pharma A/S during the first quarter worth about $288,000. ProShare Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 9.9% during the 1st quarter. ProShare Advisors LLC now owns 4,025 shares of the biotechnology company's stock worth $608,000 after purchasing an additional 361 shares during the period. Bessemer Group Inc. increased its position in Ascendis Pharma A/S by 61.0% during the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company's stock worth $132,000 after purchasing an additional 332 shares in the last quarter. Nan Fung Group Holdings Ltd purchased a new position in Ascendis Pharma A/S in the first quarter valued at approximately $2,056,000. Finally, Capital International Investors lifted its position in Ascendis Pharma A/S by 0.5% during the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company's stock valued at $331,261,000 after buying an additional 10,044 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

NASDAQ:ASND traded up $0.17 during mid-day trading on Wednesday, hitting $124.61. 135,399 shares of the company's stock traded hands, compared to its average volume of 450,620. Ascendis Pharma A/S has a 1 year low of $90.13 and a 1 year high of $161.00. The company has a market cap of $7.56 billion, a PE ratio of -15.40 and a beta of 0.66. The firm's 50 day simple moving average is $132.59 and its 200 day simple moving average is $132.38.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. On average, research analysts expect that Ascendis Pharma A/S will post -7.3 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.